Log in to your Inderes Free account to see all free content on this page.
Isofol Medical
0.66 SEK
+0.23 %
Less than 1K followers
ISOFOL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Isofol Medical
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 37.1 | 22.4 | 12.8 | 0.7 | |||
| growth-% | -39.6 % | -42.9 % | -94.4 % | ||||
| EBITDA | -166.3 | -184.7 | -202.9 | -165.8 | -41.3 | -47.2 | -56.0 |
| EBIT | -167.8 | -186.5 | -204.5 | -167.5 | -41.7 | -47.2 | -56.0 |
| Profit before taxes | -161.6 | -189.0 | -200.3 | -159.8 | -37.1 | -43.5 | -54.2 |
| Net income | -161.6 | -189.0 | -200.3 | -159.8 | -37.1 | -43.5 | -54.2 |
| EPS | -2.51 | -1.57 | -1.09 | -0.87 | -0.20 | -0.24 | -0.25 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -497.7 % | -905.4 % | -1,295.5 % | -5,737.5 % | |||
| EBIT-% | -502.4 % | -912.5 % | -1,308.3 % | -5,788.9 % | |||
| ROE | -154.0 % | -283.9 % | -62.9 % | -100.8 % | -30.5 % | -55.8 % | -50.2 % |
| ROI | -110.3 % | -127.6 % | -49.9 % | -74.8 % | -26.4 % | -44.2 % | -41.9 % |
Login required
This content is only available for logged in users